Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$5.16
-0.24 (-4.44%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $26.7M · quality 58.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
32/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.1B
P/E
57.3x
↑EV/EBITDA
19.9x
↑ROE
3.2%
↑Gross Margin
23.4%
↓Debt/Equity
0.29
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-7.6%
FCF CAGR
-32.5%
FCF margin
3.6%
FCF / Net income
0.49x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $745.3M · net income $54.3M · FCF $26.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $745.3M | $745.3M | $884.9M | $974.5M | $943.4M |
| Net Income | $54.3M | $54.3M | $86.0M | $119.9M | $109.4M |
| EBITDA | $163.2M | $163.2M | $194.6M | $231.6M | $224.8M |
| EPS | 0.09 | 0.09 | 0.13 | 0.20 | 0.18 |
| Gross Margin | 23.4% | 23.4% | 22.7% | 25.5% | 24.7% |
| Operating Margin | 10.7% | 10.7% | 12.2% | 15.4% | 14.4% |
| Net Margin | 7.3% | 7.3% | 9.7% | 12.3% | 11.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.29 | 0.29 | 0.28 | 0.28 | 0.13 |
| Current Ratio | 4.81 | 4.81 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $26.7M | $26.7M | $-8.0M | $67.2M | $86.8M |
| Returns | |||||
| ROE | 3.2% | 3.2% | 4.9% | 7.2% | 7.2% |
| Valuation | |||||
| P/E | 57.33 | 57.33 | 40.56 | 31.60 | 40.73 |
| EV/EBITDA | 19.90 | 19.90 | 17.65 | 15.15 | 19.11 |
| P/B | 1.87 | 1.87 | 2.00 | 2.28 | 2.92 |
| Growth & Yield | |||||
| Revenue Growth | -15.8% | -15.8% | -9.2% | 3.3% | — |
| EPS Growth | -34.7% | -34.7% | -32.2% | 6.2% | — |
| Dividend Yield | 0.2% | 0.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
74.1%
EPS terminal req.
$0.46
Spread vs growth
-108.8%
5Y implied EPS CAGR
44.9%
EPS terminal req.
$0.55
Spread vs growth
-79.6%
10Y implied EPS CAGR
26.2%
EPS terminal req.
$0.89
Spread vs growth
-60.9%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-8.3%
Start / end P/E
42.4x → 59.4x
EPS bridge
0.13 → 0.09
Residual
-13.9%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.